Q2 FY2026 EarningsQ2 FY2026 results showed a GAAP net loss of $24.2M, slightly missing the consensus estimate of -$23.9M. GAAP EPS was -$0.80 compared to the -$0.58 consensus, primarily due to higher-than-expected R&D and G&A expenses following the May 2026 IPO. However, the cash position is strong at $457.5M, extending the runway into 2029, and the FDA's endorsement for Phase 3 initiation of sutacimig in H2 2026 serves as a significant clinical de-risking event.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Hemab Therapeutics(COAG) the EBIT is -26.08 M (--%), Beat estimate;the EPS is -0.8 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.03B--
-0.03B--
+0.00B--%
EPSMiss expectations
-0.8--
-0.5767--
-0.2233--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf